Last reviewed · How we verify
Alimta Injectable Product — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Alimta Injectable Product (Alimta Injectable Product) — PDC*line Pharma SAS.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Alimta Injectable Product TARGET | Alimta Injectable Product | PDC*line Pharma SAS | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Alimta Injectable Product CI watch — RSS
- Alimta Injectable Product CI watch — Atom
- Alimta Injectable Product CI watch — JSON
- Alimta Injectable Product alone — RSS
Cite this brief
Drug Landscape (2026). Alimta Injectable Product — Competitive Intelligence Brief. https://druglandscape.com/ci/alimta-injectable-product. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing